7x Winner of the MMIT Patient Choice Award!

Give us a call 855.726.8479 | 412.246.9858

XOLREMDI™ (mavorixafor)
www.xolremdi.com

Xolremdi is the first treatment approved to increase the number of circulating mature neutrophils and lymphocytes in patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis).

Resources

X4 WHIM Syndrome Resources EXPLORE

PATH4WARD Genetic Testing EXPLORE

Immune Deficiency Foundation EXPLORE

The Jeffrey Modell Foundation (JMF) EXPLORE

National Neutropenia Network (NNN): EXPLORE

National Organization for Rare Disorders (NORD) EXPLORE

WHIM Schooling Accommodations EXPLORE

Finding an immunologist EXPLORE

PANTHERx Rare Contact

844-942-6628

Manufacturer Contact

X4 Pharmaceuticals
https://www.x4pharma.com/
857-529-8300

24 Summit Park Drive
Pittsburgh, PA 15275 USA

Phone: 855.726.8479
(412.246.9858)

Fax: 855.246.3986
(412.787.9400)

Email: pharmacist@pantherxrare.com

Who We Serve
Patients
Manufacturers
Prescribers
Payers

About Us
Company Overview
Our History
Our Leadership
Press Releases

Resources
Patients
Prescribers
Medications
Careers
Contact Us

Connect

Copyright © 2024 PANTHERx Rare, LLC. All rights reserved. PANTHERx RARE PHARMACY, “REINVENTING PHARMACY, REVOLUTIONIZING SPECIALTY, REDEFINING CARE”, and THE RARE DISEASE SP are registered service marks of PANTHERx Rare, LLC.

Twilio SMS Terms & Conditions | Privacy Policy | Legal Disclosure